|5.13||-0.4600||-8.23%||Vol 1.40M||1Y Perf -61.53%|
|May 18th, 2022 16:00 DELAYED|
|- -||0.25 4.87%|
|Target Price||20.80||Analyst Rating||Strong Buy 1.40|
|Potential %||305.46||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 45.03|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||1.91||Earnings Rating||Strong Buy|
|Market Cap||479.17M||Earnings Date||5th May 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.98|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.26M|
|Avg. Monthly Volume||988.81K|
|Avg. Quarterly Volume||1.07M|
Atara Biotherapeutics Inc. (NASDAQ: ATRA) stock closed at 5.59 per share at the end of the most recent trading day (a 5.47% change compared to the prior day closing price) with a volume of 1.30M shares and market capitalization of 479.17M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Atara Biotherapeutics Inc. CEO is Pascal Touchon.
The one-year performance of Atara Biotherapeutics Inc. stock is -61.53%, while year-to-date (YTD) performance is -64.53%. ATRA stock has a five-year performance of -62.98%. Its 52-week range is between 4.84 and 20.04, which gives ATRA stock a 52-week price range ratio of 1.91%
Atara Biotherapeutics Inc. currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 2.28, a price-to-sale (PS) ratio of 20.54, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -77.98%, a ROC of -107.11% and a ROE of -116.42%. The company’s profit margin is -%, its EBITDA margin is -1 417.80%, and its revenue ttm is $24.10 Million , which makes it $0.26 revenue per share.
Of the last four earnings reports from Atara Biotherapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.98 for the next earnings report. Atara Biotherapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Atara Biotherapeutics Inc. is Strong Buy (1.4), with a target price of $20.8, which is +305.46% compared to the current price. The earnings rating for Atara Biotherapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Atara Biotherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Atara Biotherapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 8.73, ATR14 : 0.59, CCI20 : -94.73, Chaikin Money Flow : -0.11, MACD : -0.85, Money Flow Index : 33.74, ROC : -12.11, RSI : 34.46, STOCH (14,3) : 30.24, STOCH RSI : 1.00, UO : 35.52, Williams %R : -69.76), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Atara Biotherapeutics Inc. in the last 12-months were: Amar Murugan (Sold 6 781 shares of value $87 823 ), Jakob Dupont (Option Excercise at a value of $143 700), Jakob Dupont (Sold 21 572 shares of value $328 599 ), Joseph Newell (Option Excercise at a value of $170 100), Joseph Newell (Sold 29 874 shares of value $491 088 ), Matthew K. Fust (Sold 13 354 shares of value $260 403 ), Pascal Touchon (Sold 39 647 shares of value $565 536 ), Utpal Koppikar (Sold 19 313 shares of value $262 429 )
Fri, 06 May 2022 01:35 GMT Analysts Top Healthcare Picks: Atara Biotherapeutics (ATRA), Cassava Sciences (SAVA)- TipRanks. All rights reserved.
Wed, 12 Jan 2022 21:45 GMT Atara Biotherapeutics (ATRA) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.